Characteristics | Men (n = 691, 80%) | Women (n = 177, 20%) | p-value |
---|---|---|---|
Age | 70 (12) | 75 (12) | < 0.001 |
Education ≥ 12 years | 267 (39) | 44 (25) | 0.154 |
Occupational status—Retired | 482 (70) | 143 (85) | 0.002 |
Disease duration in years | 12 (3) | 7 (8) | < 0.001 |
Time since last gout flare | Â | Â | 0.168 |
 > 1 year | 291 (45) | 55 (37) |  |
 1–12 months | 225 (35) | 62 (41) |  |
 Last month | 131 (20) | 33 (22) |  |
Pain NRS (0–10) | 2.7 (2.5) | 4.0 (2.8) | < 0.001 |
Global NRS (0–10) | 2.8 (2.4 | 3.8 (2.7) | < 0.001 |
Fatigue NRS (0–10) | 3.6 (2.6) | 4.4 (2.9) | < 0.001 |
HAQ score | 0.28 (0.51) | 0.63 (0.69) | < 0.001 |
Obesity, BMI ≥ 30.0 kg/m2 | 154 (22) | 60 (34) | < 0.001 |
Self-reported comorbidities | |||
 Diabetes | 157 (23) | 40 (23) | 0.654 |
 Kidney disease | 55 (8) | 18 (11) | 0.410 |
 Hypertension | 443 (64) | 118 (67) | 0.067 |
 Myocardial infarction | 104 (15) | 19 (11) | 0.311 |
 Stroke | 68 (10) | 17 (10) | 0.736 |
Pharmacological treatment | |||
 ULT—allopurinol | 341 (49) | 87 (49) | 0.963 |
 Diuretics—loop | 104 (15) | 48 (27) | 0.001 |
 Diuretics – thiazide | 69 (11) | 27 (15) | 0.156 |
Alcohol use, standard drinks a normal week |  |  | < 0.001 |
 No use | 84 (13) | 60 (36) |  |
 < 1 | 116 (17) | 59 (34) |  |
 1–4 | 190 (28) | 35 (21) |  |
 5–9 | 190 (28) | 13 (8) |  |
 10–14 | 63 (9) | 1 (1) |  |
 > 15 | 31 (5) | 1 (1) |  |